Company intelligence / Profile preview

Bioncise

Ownership: Private
Employees: ~3
Development stage: Commercial

Overview

Bioncise develops and markets innovative medical devices—particularly advanced biopsy systems—to enable personalized medicine approaches in oncology. Their products support comprehensive molecular analysis required for modern cancer diagnosis and treatment planning. The company emphasizes multidisciplinary expertise, clinical trial involvement, high standards of integrity. No clinical trial results typical to pharma/biotech are reported.

Therapeutic areas: Oncology
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships disclosed publicly as of June 2025.

Beyond the preview

Go deeper on Bioncise.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioncise.

Explore the full profile